Clinical Trials Directory

Trials / Recruiting

RecruitingNCT05813626

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma

Status
Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
89 (estimated)
Sponsor
Zhejiang Cancer Hospital · Academic / Other
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

Neoadjuvant chemotherapy plus toripalimab in patients with locoregionally advanced nasopharyngeal carcinoma

Conditions

Interventions

TypeNameDescription
DRUGToripalimabToripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy

Timeline

Start date
2023-04-03
Primary completion
2024-10-30
Completion
2027-10-30
First posted
2023-04-14
Last updated
2023-04-14

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05813626. Inclusion in this directory is not an endorsement.

Neoadjuvant Chemotherapy Plus Toripalimab in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma (NCT05813626) · Clinical Trials Directory